17.25
+1.025(+6.32%)
Currency In USD
| Previous Close | 16.23 |
| Open | 16.26 |
| Day High | 17.75 |
| Day Low | 15.64 |
| 52-Week High | 35.25 |
| 52-Week Low | 13.53 |
| Volume | 3.09M |
| Average Volume | 2.37M |
| Market Cap | 1.73B |
| PE | -3.74 |
| EPS | -4.61 |
| Moving Average 50 Days | 21.08 |
| Moving Average 200 Days | 24.86 |
| Change | 1.02 |
If you invested $1000 in Beam Therapeutics Inc. (BEAM) since IPO date, it would be worth $920 as of May 09, 2025 at a share price of $17.25. Whereas If you bought $1000 worth of Beam Therapeutics Inc. (BEAM) shares 3 years ago, it would be worth $518.17 as of May 09, 2025 at a share price of $17.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
May 06, 2025 11:00 AM GMT
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European H
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
GlobeNewswire Inc.
Apr 05, 2025 11:00 AM GMT
New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3) Fourth Coh
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
GlobeNewswire Inc.
Mar 27, 2025 8:01 PM GMT
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biote